Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
Date
2022-08-01Author
Burns, D
Anokian, E
Saunders, EJ
Bristow, RG
Fraser, M
Reimand, J
Schlomm, T
Sauter, G
Brors, B
Korbel, J
Weischenfeldt, J
Waszak, SM
Corcoran, NM
Jung, C-H
Pope, BJ
Hovens, CM
Cancel-Tassin, G
Cussenot, O
Loda, M
Sander, C
Hayes, VM
Dalsgaard Sorensen, K
Lu, Y-J
Hamdy, FC
Foster, CS
Gnanapragasam, V
Butler, A
Lynch, AG
Massie, CE
CR-UK/Prostate Cancer UK, ICGC, The PPCG,
Woodcock, DJ
Cooper, CS
Wedge, DC
Brewer, DS
Kote-Jarai, Z
Eeles, RA
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND: Germline variants explain more than a third of prostate cancer (PrCa) risk, but very few associations have been identified between heritable factors and clinical progression. OBJECTIVE: To find rare germline variants that predict time to biochemical recurrence (BCR) after radical treatment in men with PrCa and understand the genetic factors associated with such progression. DESIGN, SETTING, AND PARTICIPANTS: Whole-genome sequencing data from blood DNA were analysed for 850 PrCa patients with radical treatment from the Pan Prostate Cancer Group (PPCG) consortium from the UK, Canada, Germany, Australia, and France. Findings were validated using 383 patients from The Cancer Genome Atlas (TCGA) dataset. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A total of 15,822 rare (MAF <1%) predicted-deleterious coding germline mutations were identified. Optimal multifactor and univariate Cox regression models were built to predict time to BCR after radical treatment, using germline variants grouped by functionally annotated gene sets. Models were tested for robustness using bootstrap resampling. RESULTS AND LIMITATIONS: Optimal Cox regression multifactor models showed that rare predicted-deleterious germline variants in "Hallmark" gene sets were consistently associated with altered time to BCR. Three gene sets had a statistically significant association with risk-elevated outcome when modelling all samples: PI3K/AKT/mTOR, Inflammatory response, and KRAS signalling (up). PI3K/AKT/mTOR and KRAS signalling (up) were also associated among patients with higher-grade cancer, as were Pancreas-beta cells, TNFA signalling via NKFB, and Hypoxia, the latter of which was validated in the independent TCGA dataset. CONCLUSIONS: We demonstrate for the first time that rare deleterious coding germline variants robustly associate with time to BCR after radical treatment, including cohort-independent validation. Our findings suggest that germline testing at diagnosis could aid clinical decisions by stratifying patients for differential clinical management. PATIENT SUMMARY: Prostate cancer patients with particular genetic mutations have a higher chance of relapsing after initial radical treatment, potentially providing opportunities to identify patients who might need additional treatments earlier.
Collections
Subject
Biochemical recurrence
Germline variants
Pan Prostate Cancer Group
Prostate cancer
Germ Cells
Germ-Line Mutation
Humans
Male
Neoplasm Recurrence, Local
Phosphatidylinositol 3-Kinases
Prostatectomy
Prostatic Neoplasms
Proto-Oncogene Proteins c-akt
Proto-Oncogene Proteins p21(ras)
TOR Serine-Threonine Kinases
Research team
Oncogenetics
Language
eng
Date accepted
2022-05-10
License start date
2022-08-01
Citation
European Urology, 2022, 82 (2), pp. 201 - 211
Publisher
ELSEVIER
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by-nc-nd/4.0/
Related items
Showing items related by title, author, creator and subject.
-
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; et al. (ELSEVIER SCI LTD, 2023-05-01)BACKGROUND: Innovations in imaging and molecular characterisation together with novel treatment options have improved outcomes in advanced prostate cancer. However, we still lack high-level evidence in many areas relevant ... -
Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study
Berney, DM; Gopalan, A; Kudahetti, S; Fisher, G; Ambroisine, L; et al. (NATURE PUBLISHING GROUP, 2009-03-17)Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a ... -
Toxicity and Patient-Reported Outcomes of a Phase 2 Randomized Trial of Prostate and Pelvic Lymph Node Versus Prostate only Radiotherapy in Advanced Localised Prostate Cancer (PIVOTAL).
Dearnaley, D; Griffin, CL; Lewis, R; Mayles, P; Mayles, H; et al. (ELSEVIER SCIENCE INC, 2019-03-01)PURPOSE: To establish the toxicity profile of high-dose pelvic lymph node intensity-modulated radiation therapy (IMRT) and to assess whether it is safely deliverable at multiple centers. METHODS AND MATERIALS: In this phase ...